Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacodynamics of IV T3011 in Advanced Solid Tumors
NCT05598268Phase 2Unknown
- Sponsor
- ImmVira
- Start
- Mar 2022
- Primary completion
- Jun 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of MVR-T3011 in solid tumor (advanced stage), lung cancer, liver cancer, lymphoma, pleural mesothelioma, sponsored by ImmVira. Status: unknown.
02
Drugs
MVR-T3011
03
Conditions
solid tumor (advanced stage)lung cancerliver cancerlymphomapleural mesothelioma
Beyond the preview
Go deeper on NCT05598268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05598268.